LIGAND PHARMACEUTICALS INCORPORATED (LGND) Return on equity 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
12.2%FY2025 · since FY2016: -0.5% → 12.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 12.2% | +12.7 pp |
| FY2024 | -0.5% | -7.9 pp |
| FY2023 | 7.4% | +13.0 pp |
| FY2022 | -5.6% | -12.5 pp |
| FY2021 | 7.0% | +7.4 pp |
| FY2020 | -0.4% | -82.4 pp |
| FY2019 | 82.0% | +56.5 pp |
| FY2018 | 25.6% | +22.4 pp |
| FY2017 | 3.1% | +3.6 pp |
| FY2016 | -0.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating marginLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →